ImageneBio (IMA): Consensus Target
ImageneBio Inc develops immune-based medicines, leveraging partnerships with oncology clinics to accelerate time-to-market for its drugs. This price chart on GURU.Markets reflects a value of 17.99, while the company collaborates with medical centers to research tumor metabolism. The business's financial standing is based on clinical trial stages, remaining independent of market volatility.
Analytical breakdowns for ImageneBio Inc (IMA)
- price and consensus price forecast:
- stock exchange capitalization data:
- book value of equity indicators:
- debt obligations and liquidity statistics:
- company profitability and valuation multiples indicators:
IMA - Net Income|Expected Net Income ImageneBio Inc|IMA - P/E Multiple|Market Cap to Projected Earnings ikenaoncology.com|IMA - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Ikena Oncology, Inc.|IMA - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Ikena Oncology|IMA - Net earnings per share for the last 12 months|Quarterly EPS earnings growth ikenaoncology.com|IMA - Earnings per share growth in current year|Projected earnings per share growth rate for next year ImageneBio Inc
Fundamental company analysis:ImageneBio, IMA
This indicator represents the weighted average target price of securities, calculated based on estimates from leading analysts to determine the fundamental fairness of the market price. By analyzing the aggregated stock price forecast, an investor can assess the resilience of ImageneBio Inc. (IMA) to supply chain disruptions for oncology drug components, where a stable trend confirms the high efficiency of the company's diversified R&D infrastructure.
Competitors of ImageneBio Inc
Analyst Median Target argenx.com|Price Target Chart BioNTech BNTX|ABVX - Consensus Target|ADMA Bio - Analyst Consensus Forecast|PTGX - Analyst Consensus Forecast|Immunovant, Inc. (IMVT) - Price Target Chart|Forecast Levels Chart KNSA (kiniksa.com)|GRFS (Grifols) - Analyst Consensus Forecast|ADPT: Fair Value Consensus|Analyst Consensus Forecast CLDX|Analyst Consensus Forecast Aurinia Corp (AUPH)|Price Target Chart BioCryst BCRX|Fair Value Consensus VERA|DNTH - Price Target Chart|Pharvaris NV (PHVS) - Consensus Target|ABCL: Analyst Consensus Forecast|Tourmaline (TRML) - Analyst Consensus Forecast|Consensus Target PGEN|PHAR: Fair Value Consensus|Analyst Consensus Forecast NKTR|Analyst Median Target Upstream Bio, Inc.|Price Target Chart Zenas Biopharma, Inc. ZBIO|IMNM - Consensus Target|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|SEPN (Septerna) - Consensus Target|Pieris Pharma (PVLA) - Analyst Consensus Forecast|Price Target Chart Savara Corp|Broker Consensus Forecast RIGL (Rigel Corp)|Analyst Consensus Forecast ANAB|ATXS - Average Forecast Price|Analyst Consensus Forecast ENGN (enGene)|Analyst Median Target rapt.com (RAPT)|JBIO - Price Target Chart|Aclaris Therapeutics, Inc (ACRS) - Consensus Target|KYTX: Analyst Consensus Forecast|tizianalifesciences.com (TLSA) - Analyst Consensus Forecast|CABA (Cabaletta Bio) - Analyst Consensus Forecast|VTYX - Analyst Target Range|Analyst Consensus Forecast THTX|AVTX - Average Forecast Price|Price Target Chart Eledon Pharmaceuticals ELDN|AGEN: Broker Consensus Forecast|Climb Bio - Analyst Consensus Forecast|Average Forecast Price zurabio.com|ATYR: Analyst Consensus Forecast|ADAG (Adagene Inc.) - Price Target Chart|STTK (Shattuck Labs Inc) - Analyst Consensus Forecast|Equillium Bio (EQ) - Analyst Median Target|Price Target Chart Connect Biopharma (CNTB)|IMUX - Average Forecast Price|Atara Bio - Consensus Target|Fair Value Consensus IFRX|X4 Pharmaceuticals - Analyst Consensus Forecast|Analyst Median Target Adicet Bio ACET|celularity.com (CELU) - Price Target Chart|Broker Consensus Forecast INMB|BRNS (Barinthus Bio) - Analyst Consensus Forecast|Consensus Target Kezar Life Sciences Inc (KZR)|Analyst Consensus Forecast SABS|Analyst Median Target akaritx.com|Price Target Chart Enlivex Therapeutics Ltd. ENLV|QTTB - Consensus Target|GeoVax Labs Inc - Analyst Consensus Forecast|EDSA - Analyst Consensus Forecast|iBio, Inc. (IBIO) - Price Target Chart|Forecast Levels Chart CARM (Carisma Therapeutics Inc.)|XTLB (XTL Biopharmaceuticals Ltd.) - Analyst Consensus Forecast|BOLT: Fair Value Consensus|Analyst Consensus Forecast HCWB|Analyst Consensus Forecast aptevotherapeutics.com (APVO)|Price Target Chart AIM ImmunoTech AIM|Fair Value Consensus ADTX|GRI - Price Target Chart|XORTX Therapeutics Inc (XRTX) - Consensus Target|HIND: Analyst Consensus Forecast|Revelation Biosciences Corp (REVB) - Analyst Consensus Forecast|Consensus Target INDP|SCNI: Fair Value Consensus|Analyst Consensus Forecast CALI|Analyst Median Target affimed.com|Price Target Chart Allakos ALLK|HOOK - Consensus Target|IGMS - Price Target Chart|iteostherapeutics.com (ITOS) - Consensus Target|OCEA (Ocean Biomedical) - Consensus Target|TC BioPharm (Holdings) Plc (TCBP) - Analyst Consensus Forecast|Price Target Chart Third Harmonic Bio, Inc
